Mohindru Mani 4

What Happened
Mohindru Mani, Interim CEO and a director of Cardiff Oncology (CRDF), was granted 200,000 shares as an award on February 17, 2026. The Form 4 reports the acquisition as a derivative award at $0.00 per share (total reported acquisition value $0). This was an equity award/grant (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-17; Form 4 filed with the SEC on 2026-02-18 (appears timely).
• Transaction type/code: Award/Grant (A); classified as a derivative acquisition (not a market trade).
• Shares granted: 200,000; reported acquisition price: $0.00 (insider cost reported as zero).
• Shares owned after the transaction: Not specified in the excerpt provided.
• Notable footnotes: None provided in the excerpt (no 10b5-1, tax-withholding, or cashless-sale notes shown).

Context
Derivative/award grants commonly represent restricted stock, restricted stock units (RSUs), or similar compensation that may vest over time and are not the same as an immediate market purchase. A reported $0 acquisition price reflects the insider’s cost or grant accounting on the Form 4, not necessarily the fair market value of the shares. Such compensation grants are routine for executives and do not by themselves indicate a buy or sell signal.